Biogen to Advance Alzheimer's Drug Diranersen to Late-Stage Despite Phase 2 Miss
BIIB sits 88% above its 52-week low of $119.18.
Summary
Biogen announced its decision to advance the experimental Alzheimer's drug, Diranersen, into late-stage trials, despite the treatment failing to meet its primary endpoint in a mid-stage (Phase 2 Celia) study. The drug did not show that higher doses were more effective than lower ones in tracking dementia severity. This strategic decision to continue development, despite the mixed results, is a significant update for the company's pipeline, especially given the high unmet need in Alzheimer's. The market reacted positively, with shares up over 6% in premarket trading, indicating that investors view the continuation of the program as a net positive, outweighing the mid-stage trial miss. Traders will now watch for further details on the late-stage trial design and future data readouts.
At the time of this announcement, BIIB was trading at $223.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.2B. The 52-week trading range was $119.18 to $205.97. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.